Srinagar Magazine

DelveInsight’s “Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Membranous Nephropathy, historical and forecasted epidemiology as well as the Membranous Nephropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Membranous Nephropathy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/membranous-nephropathy-market

Some of the key facts of the Membranous Nephropathy Market Report:

• The Membranous Nephropathy market size is anticipated to grow with a significant CAGR during the study period (2022-2036).

• In April 2026, Climb Bio announced that the US FDA had granted Fast Track Designation (FTD) to budoprutug for the treatment of PMN.

• In February 2026, Roche announced that the Phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint, showing statistically significant and clinically meaningful results with obinutuzumab.

• Roche in its Q1 2026 presentation anticipates BLA submission for obinutuzumab in membranous nephropathy in 2026.

• Biogen in its Q1 2026 busines update anticipates felzartamab approval in 2028-2030 in primary membranous nephropathy.

• In November 2025, povetacicept was granted FTD by the US FDA in PMN.

• In June 2025, Biogen announced the initiation of dosing in the global clinical study, PROMINENT. The Phase III study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with PMN. Phase III data expected to read out in 2029.

• In February 2025, Genentech, a subsidiary of Roche, has submitted positive Phase III data to the U.S. Food and Drug Administration (FDA) as it seeks to enter the lucrative lupus market with its CD20-targeting drug, Gazyva (obinutuzumab). Additionally, the company is investigating Gazyva for other autoimmune conditions, including systemic lupus erythematosus (SLE), childhood-onset idiopathic nephrotic syndrome, membranous nephropathy, and pediatric lupus nephritis.

• IMNis often characterized by the antigens associated with the sub-epithelial immune complex deposits, some of them being PLA2R and THSD7A. Among the 7MM, PLA2R antigen accounted for maximum number of cases of IMN.

• In 2025, IMN accounted for ~85% of total membranous nephropathy cases in the US, while secondary membranous nephropathy contributed to the remaining ~15%, highlighting the dominance of autoimmune origin in disease prevalence.

• Across EU4 and the UK, nearly 20,000 IMN patients tested positive for the PLA2R antigen, while around 1,000 were associated with THSD7A, emphasizing the diagnostic importance of these target antigens in IMN.

• Data from Japan indicates that the prevalence of IMN is expected to remain relatively consistent throughout the forecast period from 2026 to 2036, reflecting a stable epidemiological trend without significant increases or decreases in disease occurrence across the population during this timeframe.

• Key Membranous Nephropathy Companies: Roche, BeOne Medicines, Biogen, Vertex Pharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Climb Bio, argenx, Tenet Medicines, Mario Negri Institute for Pharmacological, Beijing Mabworks Biotech, Shanghai Jiaolian Drug R&D, Cerium Pharmaceuticals, BeiGene, Hoffmann-La Roche, Reistone Biopharma, SynAct Pharma, Alpine Immune Sciences, Walden Biosciences, Hansa Biopharma AB, and others

• Key Membranous Nephropathy Therapies: Obinutuzumab (GAZYVA/GAZYVARO, RG7159, GA101), Zanubrutinib (BRUKINSA), Felzartamab, Povetacicept, ALXN1920, Budoprutug, efgartigimod IV, VB119, MOR202, MIL62, B007, SNP-ACTH (1-39) Gel, Zanubrutinib, Obinutuzumab, SHR1459, AP1189, povetacicept, WAL0921, Imlifidase, and others

• The Membranous Nephropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Membranous Nephropathy pipeline products will significantly revolutionize the Membranous Nephropathy market dynamics.

Membranous Nephropathy Overview

Membranous Nephropathy is a chronic kidney disorder where the body’s immune system attacks the membranes in the glomeruli the tiny filtering units in the kidneys. This leads to thickening of the glomerular basement membrane, causing protein to leak into the urine (proteinuria). It is a common cause of nephrotic syndrome in adults. The condition can be primary (idiopathic) or secondary to other diseases like lupus, infections, cancer, or use of certain medications. Symptoms include swelling (especially in the legs), fatigue, and foamy urine. Treatment depends on the severity and underlying cause, ranging from observation to immunosuppressive therapy.

To Know in detail about the Membranous Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Membranous Nephropathy Market Forecast

Membranous Nephropathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Membranous Nephropathy Epidemiology Segmentation:

The Membranous Nephropathy market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Membranous Nephropathy Prevalent Cases

• Membranous Nephropathy Types-specific Prevalent Cases

• Idiopathic Membranous Nephropathy (IMN) Prevalent Cases by Antigens

• Membranous Nephropathy Treated Cases

Download the report to understand which factors are driving Membranous Nephropathy epidemiology trends @ Membranous Nephropathy Epidemiology Forecast

Membranous Nephropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Membranous Nephropathy market or expected to get launched during the study period. The analysis covers Membranous Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Membranous Nephropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Membranous Nephropathy Therapies and Key Companies

• Obinutuzumab (GAZYVA/GAZYVARO, RG7159, GA101): Roche

• Zanubrutinib (BRUKINSA): BeOne Medicines

• Felzartamab: Biogen

• Povetacicept: Vertex Pharmaceuticals

• ALXN1920: AstraZeneca / Alexion Pharmaceuticals

• Budoprutug: Climb Bio

• GAZYVA (obinutuzumab): Hoffmann-La Roche

• MOR202 (felzartamab): MorphoSys/HI-Bio

• efgartigimod IV: argenx

• VB119: Tenet Medicines

• MOR202: Mario Negri Institute for Pharmacological

• MIL62: Beijing Mabworks Biotech

• B007: Shanghai Jiaolian Drug R&D

• SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals

• Zanubrutinib: BeiGene

• Obinutuzumab: Hoffmann-La Roche

• SHR1459: Reistone Biopharma

• AP1189: SynAct Pharma

• povetacicept: Alpine Immune Sciences

• WAL0921: Walden Biosciences

• Imlifidase: Hansa Biopharma AB

Discover more about therapies set to grab major Membranous Nephropathy market share @ Membranous Nephropathy Treatment Landscape

Membranous Nephropathy Market Drivers

• Increasing Diagnosis of Autoimmune Kidney Diseases: Improved awareness and diagnostic capabilities are leading to earlier detection of membranous nephropathy (MN), supporting market growth.

• Advancements in Biomarker-Based Diagnosis: The use of biomarkers such as anti-PLA2R and anti-THSD7A antibodies has enhanced disease identification, monitoring, and treatment selection.

• Emergence of Targeted Therapies: Development of novel immunomodulatory and B-cell-targeted therapies is expanding treatment options beyond conventional immunosuppressants.

• Growing Research and Clinical Trial Activity: Increased investment in rare kidney disease research and a robust pipeline of emerging therapies are driving innovation in the MN market.

Membranous Nephropathy Market Barriers

• Rare Disease Prevalence: The relatively low patient population limits market size and can reduce commercial incentives for therapy development.

• High Cost of Advanced Therapies: Biologics and targeted treatments may impose significant financial burdens on patients and healthcare systems.

• Complex Disease Heterogeneity: Variability in disease progression, response to treatment, and relapse rates can complicate clinical management and therapeutic development.

• Limited Long-Term Clinical Data: Many emerging therapies still require extensive long-term efficacy and safety data before achieving widespread adoption.

Scope of the Membranous Nephropathy Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Membranous Nephropathy Companies: Roche, BeOne Medicines, Biogen, Vertex Pharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Climb Bio, argenx, Tenet Medicines, Mario Negri Institute for Pharmacological, Beijing Mabworks Biotech, Shanghai Jiaolian Drug R&D, Cerium Pharmaceuticals, BeiGene, Hoffmann-La Roche, Reistone Biopharma, SynAct Pharma, Alpine Immune Sciences, Walden Biosciences, Hansa Biopharma AB, and others

• Key Membranous Nephropathy Therapies: Obinutuzumab (GAZYVA/GAZYVARO, RG7159, GA101), Zanubrutinib (BRUKINSA), Felzartamab, Povetacicept, ALXN1920, Budoprutug, efgartigimod IV, VB119, MOR202, MIL62, B007, SNP-ACTH (1-39) Gel, Zanubrutinib, Obinutuzumab, SHR1459, AP1189, povetacicept, WAL0921, Imlifidase, and others

• Membranous Nephropathy Therapeutic Assessment: Membranous Nephropathy current marketed and Membranous Nephropathy emerging therapies

• Membranous Nephropathy Market Dynamics: Membranous Nephropathy market drivers and Membranous Nephropathy market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Membranous Nephropathy Unmet Needs, KOL’s views, Analyst’s views, Membranous Nephropathy Market Access and Reimbursement

To know more about Membranous Nephropathy companies working in the treatment market, visit @ Membranous Nephropathy Clinical Trials and Therapeutic Assessment

Table of Contents

1. Membranous Nephropathy Market Report Introduction

2. Executive Summary for Membranous Nephropathy

3. SWOT analysis of Membranous Nephropathy

4. Membranous Nephropathy Patient Share (%) Overview at a Glance

5. Membranous Nephropathy Market Overview at a Glance

6. Membranous Nephropathy Disease Background and Overview

7. Membranous Nephropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Membranous Nephropathy

9. Membranous Nephropathy Current Treatment and Medical Practices

10. Membranous Nephropathy Unmet Needs

11. Membranous Nephropathy Emerging Therapies

12. Membranous Nephropathy Market Outlook

13. Country-Wise Membranous Nephropathy Market Analysis (2022–2036)

14. Membranous Nephropathy Market Access and Reimbursement of Therapies

15. Membranous Nephropathy Market Drivers

16. Membranous Nephropathy Market Barriers

17. Membranous Nephropathy Appendix

18. Membranous Nephropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/